San Rafael, California, United States
Alexander Hardy serves as President and Chief Executive Officer of BioMarin and a member of the company’s Board of Directors. Alexander joined BioMarin in December 2023 after more than 30 years in the global biopharmaceutical industry. Prior to BioMarin, he spent nearly 20 years at Genentech and Roche, most recently serving as Chief Executive Officer of Genentech. During his time as Genentech’s CEO, he oversaw the successful launch of 10 innovative medicines and spearheaded the company’s entrance into several new therapeutic areas. Prior to that, Alexander led Roche’s Global Product Strategy organization and, before that served as head of Asia Pacific for Roche. Earlier in his career, Alexander held a number of international leadership roles at Novartis. Alexander serves on the Board of Directors for the Pharmaceutical Research and Manufacturers of America (PhRMA). Throughout his career, Alexander has championed a vibrant company culture that inspires employees to improve human health. He is an advocate for diversity, equity and inclusion to promote belonging within organizations and advance inclusive research across the biopharmaceutical industry. Alexander completed his undergraduate education at the University of Cambridge in the UK and earned his M.B.A. at the University of Michigan’s Ross School of Business. He lives in the San Francisco Bay Area with his wife and three daughters.
Responsible for business unit covering neuroscience, cardio-metabolism, infectious disease, hepatology, transplantation, growth hormone and thrombolytic therapy areas.
Responsible for sales and marketing teams for Herceptin, Perjeta (launch) and Kadcyla (launch)
Responsible for the Tamiflu franchise in the US.